SLC19A1 and Thymidylate Synthase Polymorphisms Do not Predict Survival Outcome in Non-Small-Cell Lung Cancer Treated with Pemetrexed-Cisplatin Chemotherapy Regimen
Background: Lung cancer is the leading cause of cancer deaths worldwide. Pharmacogenomics plays an important role in tailoring cancer patients’ treatment. Pemetrexed is widely used in first- and second-line chemotherapy of non-small cell lung cancer (NSCLC); however, there is no available predictive...
Main Authors: | Mohammad Hadi Abbasian, Nafiseh Ansarinejad, Tayeb Ramim, Farshid Fardad, Bahareh Abbasi |
---|---|
Format: | Article |
Language: | English |
Published: |
Shiraz University of Medical Sciences
2023-01-01
|
Series: | Middle East Journal of Cancer |
Subjects: | |
Online Access: | https://mejc.sums.ac.ir/article_48279_6906424d8d389efe87089f7d09f4c56e.pdf |
Similar Items
-
Thymidylate synthase inhibitors for thoracic tumors
by: Peters Godefridus J., et al.
Published: (2013-06-01) -
Activity of pemetrexed in recurrent, metastatic sacral chordoma: A case report
by: Dominique G. Celestino, et al.
Published: (2025-03-01) -
Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC
by: Wang Xia, et al.
Published: (2013-01-01) -
Effect of PD-L1 expression on the efficacy of pemetrexed-based chemotherapy in patients with advanced lung adenocarcinoma and its mechanism
by: SHI Maolin , BAI Yudi , WANG Chao , LI Siqi , ZHOU Daijun , PENG Jingjing , SUN Feifan , LI Dong , ZHANG Tao
Published: (2021-04-01) -
Relationship between the Expression of the Thymidylate Synthase and the Prognosis of Gastric Cancer Patients Treated with Combinational Chemotherapy Regimen Including Fluorouracil, Docetaxel and Cisplatin
by: Mozaffar Aznab, et al.
Published: (2020-07-01)